电压门控钠离子通道亚型Nav1.5在口腔鳞状细胞癌淋巴结转移中作用的初步研究  

Preliminary study on the role of voltage-gated sodium channel subtype Nav1.5 in lymph node metastasis of oral squamous cell carcinoma

作　　者：刘玮佳 许乐[1] 祝心威[1] 陈小芳[1] 王晖 蒋勇[1] 

机构地区：[1]安徽医科大学第四附属医院口腔科,合肥230032

出　　处：《中华口腔医学杂志》2017年第3期188-193,共6页Chinese Journal of Stomatology

基　　金：安徽省自然科学基金（1508085MH187）

摘　　要：目的 通过检测电压门控钠离子通道（voltage-gated sodium channels,VGSC）亚型Nav1.5在口腔鳞状细胞癌（oral squamous cell carcinoma,OSCC）中的表达,探讨其对OSCC的发生和淋巴结转移的作用.方法 收集安徽医科大学第一附属医院口腔颌面外科26例患有原发性低分化OSCC的患者术中切除的肿瘤上皮组织作为试验组,并按肿瘤组织有无淋巴结转移将试验组分为无转移组（16例）和有转移组（10例）;另收集10例正常口腔黏膜组织（来源于颌面部外伤、拔牙等术中切除的上皮组织）作为对照组,采用实时荧光定量PCR（quantitative real-time PCR,qPCR）、蛋白质印迹法、免疫组化法、酶联免疫吸附测定（enzyme-linked immunosorbent assay,ELISA）法分别检测Nav1.5在对照组及试验各组中mRNA或蛋白的表达水平,并对各组间差异进行单因素方差分析.结果 在对照组、无转移组和有转移组中,qPCR法检测Nav1.5 mRNA的相对表达量分别为1.054±0.162、2.311±0.134和4.462±0.362,无转移组和有转移组均显著高于与对照组（P=0.037;P=0.029）,且有转移组显著高于无转移组（P=0.031）.蛋白质印迹法检测结果显示,对照组、无转移组和有转移组Nav1.5蛋白的相对表达量分别为0.080±0.010、0.143±0.005和0.253±0.015,无转移组和有转移组均显著高于与对照组（P=0.034;P=0.026）,有转移组显著高于无转移组（P=0.033）.免疫组化检测结果显示,对照组和试验组的Nav1.5蛋白阳性表达率分别为1/10和92%（24/26）,二者差异有统计学意义（P=0.016）.有转移组和无转移组的Nav1.5蛋白阳性表达差异亦有统计学意义（P=0.028）.ELISA法结果显示,Nav1.5在对照、无转移和有转移组中的表达分别为（0.834±0.103）、（1.578±0.167）和（3.882±0.422）μg/L,无转移组和有转移组均显著高于对照组（P=0.041;P=0.032）,有转移组显著高于无转移组（P=0.030）.结论Nav1.5在低分化OSCC中高表达且�Objective To investigate the relationship between the expression of voltage-gated sodium channel subtype Nav1.5 in oral squamous cell carcinoma （OSCC） and the occurrence and lymph node metastasis of OSCC. Methods Totally 10 samples of normal oral mucosa tissue as control group, 26 samples of OSCC as the experimental group was divided into non-metastatic group （n=16） and metastatic group （n=10） according to the presence or absence of lymph node metastasis. Quantitative real-time PCR （qPCR）, Western blotting, immunohistochemistry, and enzyme-linked immunosorbent assay （ELISA） were used to detect the expression of Nav1.5 in control group and experimental groups at mRNA and protein levels. The data were analyzed by one-way analysis. Results The expression of Nav1.5 mRNA in the experimental group （non-metastatic group： 2.311 ± 0.134, metastatic group： 4.462 ± 0.362） was higher than those in the control group （1.054 ± 0.162） （P=0.037; P=0.029）, and the metastasis group was significantly higher than the non-metastasis group （P=0.031）. Western blotting showed the expression of Nav1.5 in experimental groups （non-metastatic：0.143 ± 0.005, metastatic：0.253 ± 0.015） was up-regulated significantly compared with control group （0.080±0.010） （P=0.034, P=0.026）, and the metastasis group was significantly higher than the non-metastasis group （P=0.033）. The immunohistochemistry show the positive expression rates of Nav1.5 in normal and OSCC tissues were 1/10 and 92%（24/26）.The differences were statistically significant （P=0.016）, and the metastasis group was significantly higher than the non-metastasis group （P=0.028）. The ELISA results revealed that the level of Nav1.5 in control was control group （0.834±0.103）μg/L, in non-metastasis group was （1.578±0.167）μg/L, in metastasis group was （3.882±0.422）μg/L （P=0.041;P=0.032）, and the metastasis group was significantly higher than the non-metastasis group （P=0.030）. Conclusions Nav1.

关 键 词：癌 鳞状细胞 淋巴转移 钠通道 电压门控 

分 类 号：R739.8[医药卫生—肿瘤]